NCT01133574View on ClinicalTrials.gov

This is a Single Ascending Dose Tolerance Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Cognition Disorders
Interventions
DRUG

SLV354 capsules

20 mg

DRUG

SLV354 capsules

60 mg

DRUG

SLV354 capsules

120 mg

DRUG

SLV354 capsules

250 mg

DRUG

SLV354 capsules

500 mg

DRUG

SLV354 capsules

750 mg

DRUG

SLV354 capsules

1000 mg

DRUG

SLV354 capsules

1250 mg

DRUG

Placebo capsules

placebo

DRUG

SLV354 capsules

low dose group 1

DRUG

SLV354 capsules

high dose group 1

DRUG

SLV354 capsules

low dose group 2

DRUG

SLV354 capsules

high dose group 2

DRUG

Placebo capsules

placebo

Trial Locations (1)

SE1 9RT

Site Reference ID/Investigator# 62002, London

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Abbott

INDUSTRY